Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
2.
Pharmacogenomics J ; 16(6): 530-535, 2016 11.
Article in English | MEDLINE | ID: mdl-26345518

ABSTRACT

Anthracyclines are efficient chemotherapy agents. However, their use is limited by anthracycline-induced cardiotoxicity (CT). We investigated the influence of polymorphisms in doxorubicin metabolic and functional pathways on late-onset CT as estimated by echocardiography in 251 childhood acute lymphoblastic leukemia (cALL) patients. Association analyses revealed a modulating effect of two variants: A-1629 T in ABCC5, an ATP-binding cassette transporter, and G894T in the NOS3 endothelial nitric oxide synthase gene. Individuals with the ABCC5 TT-1629 genotype had an average of 8-12% reduction of ejection (EF) and shortening fractions (SF; EF: P<0.0001, and SF: P=0.001, respectively). A protective effect of the NOS3 TT894 genotype on EF was seen in high-risk patients (P=0.02), especially in those who did not receive dexrazoxane (P=0.002). Analysis of an additional cohort of 44 cALL patients replicated the ABCC5 association but was underpowered for NOS3. In summary, we identified two biomarkers that may contribute to cALL anthracycline CT risk stratification.


Subject(s)
Antibiotics, Antineoplastic/adverse effects , Doxorubicin/adverse effects , Heart Diseases/genetics , Multidrug Resistance-Associated Proteins/genetics , Nitric Oxide Synthase Type III/genetics , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Adolescent , Adult , Cardiotonic Agents/therapeutic use , Cardiotoxicity , Child , Child, Preschool , Dexrazoxane/therapeutic use , Female , Genetic Predisposition to Disease , Heart Diseases/chemically induced , Heart Diseases/enzymology , Heart Diseases/prevention & control , Heterozygote , Homozygote , Humans , Infant , Male , Multidrug Resistance-Associated Proteins/metabolism , Myocardial Contraction , Nitric Oxide Synthase Type III/metabolism , Pharmacogenetics , Phenotype , Protective Factors , Risk Assessment , Risk Factors , Stroke Volume , Time Factors , Treatment Outcome , Ventricular Function, Left , Young Adult
3.
Clin Genet ; 73(6): 516-27, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18462450

ABSTRACT

Congenital heart disease is the commonest malformation in humans and contributes greatly to the burden of disease in infancy. Increasingly, developmental origins are also implicated in heart disease in adults. Significant advances have been made over the past decade in elucidating morphogenetic events of heart formation and their underlying molecular cascades, mostly in animal models. Clinical studies are increasingly successful in quantifying and unraveling genetic factors. This review focuses on recent progress made in understanding the genetic underpinnings of normal and abnormal heart formation and highlights the importance of understanding these mechanisms to improve patient management.


Subject(s)
Heart Defects, Congenital/genetics , Animals , Chromosome Aberrations , Heart/embryology , Heart/growth & development , Humans , Morphogenesis/genetics , Mutation
4.
Genomics ; 83(6): 1053-62, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15177558

ABSTRACT

Canine tricuspid valve malformation (CTVM) maps to canine chromosome 9 (CFA9), in a region syntenic with gene-dense human chromosome 17q. To define synteny blocks, we analyzed 148 markers on CFA9 using radiation hybrid mapping and established a four-way comparative map for human, mouse, rat, and dog. We identified a large number of rearrangements, allowing us to reconstruct the evolutionary history of individual synteny blocks and large chromosomal segments. A most parsimonious rearrangement scenario for all four species reveals that human chromosome 17q differs from CFA9 and the syntenic rodent chromosomes through two macroreversals of 9.2 and 23 Mb. Compared to a recovered ancestral gene order, CFA9 has undergone 11 reversals of <3 Mb and 2 reversals of >3 Mb. Interspecies reuse of breakpoints for micro- and macrorearrangements was observed. Gene order and content of the ctvm interval are best extrapolated from murine data, showing that multispecies genome rearrangement scenarios contribute to identifying gene content in canine mapping studies.


Subject(s)
Chromosomes, Mammalian/genetics , Evolution, Molecular , Gene Order/genetics , Gene Rearrangement/genetics , Tricuspid Atresia/genetics , Animals , Base Sequence , Chromosome Mapping/methods , Computational Biology , Dogs , Humans , Mice , Molecular Sequence Data , Phylogeny , Rats , Sequence Alignment , Sequence Homology
6.
J Med Genet ; 40(5): 320-4, 2003 May.
Article in English | MEDLINE | ID: mdl-12746392

ABSTRACT

BACKGROUND: Ebstein anomaly of the tricuspid valve is a congenital cardiac malformation characterised by downward displacement of the attachment of the septal and posterior leaflets of the tricuspid valve. Canine tricuspid valve malformation (CTVM) is morphologically similar to Ebstein anomaly; familial occurrence of CTVM has been described. Several observations suggest a genetic cause but most cases appear to be sporadic. METHODS: Three purebred Labrador Retriever kindreds enriched for CTVM underwent clinical examination and echocardiography. DNA was extracted from whole blood. Genotyping was carried out using polymorphic repeat markers with an average spacing of 15 cM and polymorphic information content of 0.74. RESULTS: Pedigree analysis identified CTVM segregating as an autosomal dominant trait with reduced penetrance. Genome wide linkage analysis in one kindred identified a CTVM susceptibility locus on dog chromosome 9 (CFA9) with a maximum multipoint lod score of 3.33. The two additional kindreds showed a conserved disease haplotype. CONCLUSIONS: This study identifies a CTVM susceptibility locus on CFA9 and a founder effect in apparently unrelated Labrador Retriever kindreds. These results provide the basis for a positional candidate cloning effort to identify the CTVM disease gene. Identification of the CTVM gene will permit mutation screening of patients with Ebstein anomaly, which should provide additional insights into the genetic programmes of valve development.


Subject(s)
Chromosome Mapping , Chromosomes, Mammalian/genetics , Disease Models, Animal , Ebstein Anomaly/genetics , Ebstein Anomaly/veterinary , Tricuspid Valve/abnormalities , Animals , Dogs , Ebstein Anomaly/diagnostic imaging , Female , Founder Effect , Genes, Dominant , Genetic Predisposition to Disease , Haplotypes/genetics , Humans , Lod Score , Male , Pedigree , Penetrance , Tricuspid Valve/diagnostic imaging , Ultrasonography
8.
Am J Physiol Heart Circ Physiol ; 280(5): H2342-9, 2001 May.
Article in English | MEDLINE | ID: mdl-11299240

ABSTRACT

Although the role of PGE2 in maintaining ductus arteriosus (DA) patency is well established, the specific PGE2 receptor subtype(s) (EP) involved have not been clearly identified. We used late gestation fetal and neonatal lambs to study developmental regulation of EP receptors. In the fetal DA, radioligand binding and RT-PCR assays virtually failed to detect EP1 but detected EP2, EP3D, and EP4 receptors in equivalent proportions. In the newborn lamb, DA total density was one-third of that found in the fetus and only EP2 was detected. Stimulation of EP2 and EP4 increased cAMP formation and was associated with DA relaxation. Though stimulation of EP3 inhibited cAMP formation, it surprisingly relaxed the fetal DA both in vitro and in vivo. This EP3-induced relaxation was specifically diminished by the ATP-sensitive K(+) (K(ATP)) channel blocker glibenclamide. In conclusion, PGE2 dilates the late gestation fetal DA through pathways that involve either cAMP (EP2 and EP4) or K(ATP) channels (EP3). The loss of EP3 and EP4 receptors in the newborn DA is consistent with its decreased responsiveness to PGE2.


Subject(s)
Alprostadil/analogs & derivatives , Ductus Arteriosus/metabolism , Receptors, Prostaglandin E/metabolism , Xanthones , 8-Bromo Cyclic Adenosine Monophosphate/pharmacology , Adenosine Triphosphate/metabolism , Alprostadil/pharmacology , Animals , Animals, Newborn , Anti-Arrhythmia Agents/pharmacology , Anti-Ulcer Agents/pharmacology , Binding, Competitive , Biphenyl Compounds/pharmacology , Colforsin/pharmacology , Dinoprost/analogs & derivatives , Dinoprost/metabolism , Dinoprost/pharmacology , Female , Fetus/chemistry , Fetus/metabolism , Polymerase Chain Reaction , Potassium Channels/metabolism , Pregnancy , Prostaglandin Antagonists/pharmacology , Prostaglandins E, Synthetic/pharmacology , Radioligand Assay , Receptors, Prostaglandin E/analysis , Receptors, Prostaglandin E/genetics , Sheep , Tritium , Vasoconstriction/drug effects , Vasoconstriction/physiology , Xanthenes/pharmacology
9.
Pediatr Cardiol ; 22(6): 525-6, 2001.
Article in English | MEDLINE | ID: mdl-11894162

ABSTRACT

Functional pulmonary atresia is characterized by a structurally normal pulmonary valve not opening during right ventricular ejection. We report this rare condition in a premature newborn of a twin pregnancy, in which fetal echocardiography findings were consistent with critical pulmonary stenosis. After birth, features of neonatal Marfan's syndrome were noted. Echocardiography showed a morphologically normal but immobile pulmonary valve with continuous regurgitation. Right ventricular pressure was subsystemic. In this case, initial treatment with nitric oxide, followed by pharmacological duct closure, was successful. Differentiating between anatomic and functional pulmonary valve atresia may be difficult. The echocardiographic criteria are discussed.


Subject(s)
Marfan Syndrome/complications , Nitric Oxide/therapeutic use , Pulmonary Atresia/drug therapy , Vasodilator Agents/therapeutic use , Administration, Inhalation , Echocardiography , Female , Humans , Infant, Newborn , Infant, Premature , Nitric Oxide/administration & dosage , Pulmonary Atresia/etiology , Pulmonary Atresia/physiopathology , Vasodilator Agents/administration & dosage
10.
Eur J Pediatr ; 154(5): 340-5, 1995 May.
Article in English | MEDLINE | ID: mdl-7641762

ABSTRACT

To evaluate the long-term effects of anthracyclines on the myocardium of the young child we examined 34 patients who had been treated with anthracyclines in childhood. In addition to anthracycline, the patients were treated with other potentially cardiotoxic substances within the framework of different protocols. The mean cumulative anthracycline dose was 128.6 mg/m2, the average age at onset of chemotherapy 4.2 years, and the time interval after discontinuation of treatment 9.0 years. The cardiological examination consisted of a physical examination, electrocardiography and echocardiography, including Doppler and bio-impedance cardiography. The patients were studied at rest and after physical exercise with a cycle ergometer test in a supine position. The results of the physical examination, the electrocardiogram at rest and the 24 h Holter monitoring were normal. The left ventricular enddiastolic diameter, shortening fraction, velocity of fibre shortening (VCF), the diastolic flow profile at the mitral valve level and the cardiac stroke volume at rest were also normal. However, the shortening fraction (SF) was below the margin of 2 standard deviations in two patients and the VCF in three patients. There was a significant reduction in septal thickness, (-1.4 SD, P < 0.0004), in the width of left ventricular posterior wall (-1.5 SD, P > 0.0002) and in the left ventricular myocardial mass (-0.76 SD, P = 0.0042). Physical working capacity was normal. Immediately after physical stress the expected rise of SF and VCF did not occur and the SF fell below the values at rest. In comparison to a healthy control group the SF and the VCF were markedly decreased (P > 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Cardiac Output, Low/chemically induced , Cardiomyopathy, Dilated/chemically induced , Daunorubicin/adverse effects , Heart/drug effects , Adolescent , Age Factors , Cardiac Output, Low/diagnostic imaging , Cardiac Output, Low/physiopathology , Cardiography, Impedance , Cardiomyopathy, Dilated/diagnostic imaging , Cardiomyopathy, Dilated/physiopathology , Child , Child, Preschool , Dose-Response Relationship, Drug , Doxorubicin/adverse effects , Echocardiography, Doppler , Exercise Test , Female , Heart/growth & development , Heart/physiopathology , Heart Function Tests , Humans , Male , Medical History Taking , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...